1137 related articles for article (PubMed ID: 23603534)
21. Nano-ophthalmology: Applications and considerations.
Kamaleddin MA
Nanomedicine; 2017 May; 13(4):1459-1472. PubMed ID: 28232288
[TBL] [Abstract][Full Text] [Related]
22. Nanomedicines for intranasal delivery: understanding the nano-bio interactions at the nasal mucus-mucosal barrier.
Hua T; Li S; Han B
Expert Opin Drug Deliv; 2024 Apr; 21(4):553-572. PubMed ID: 38720439
[TBL] [Abstract][Full Text] [Related]
23. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
24. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
25. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.
Bravo-Osuna I; Andrés-Guerrero V; Pastoriza Abal P; Molina-Martínez IT; Herrero-Vanrell R
Drug Deliv Transl Res; 2016 Dec; 6(6):686-707. PubMed ID: 27766598
[TBL] [Abstract][Full Text] [Related]
27. Nanotechnology approaches for ocular drug delivery.
Xu Q; Kambhampati SP; Kannan RM
Middle East Afr J Ophthalmol; 2013; 20(1):26-37. PubMed ID: 23580849
[TBL] [Abstract][Full Text] [Related]
28. Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye.
Fangueiro JF; Veiga F; Silva AM; Souto EB
Curr Pharm Des; 2016; 22(9):1135-46. PubMed ID: 26675225
[TBL] [Abstract][Full Text] [Related]
29. Ocular Drug Delivery.
Yavuz B; Kompella UB
Handb Exp Pharmacol; 2017; 242():57-93. PubMed ID: 27783270
[TBL] [Abstract][Full Text] [Related]
30. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy.
Campos EJ; Campos A; Martins J; Ambrósio AF
Nanomedicine; 2017 Aug; 13(6):2101-2113. PubMed ID: 28428052
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicines for kidney diseases.
Williams RM; Jaimes EA; Heller DA
Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
[TBL] [Abstract][Full Text] [Related]
32. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.
Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK
Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247
[TBL] [Abstract][Full Text] [Related]
33. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.
Yasin MN; Svirskis D; Seyfoddin A; Rupenthal ID
J Control Release; 2014 Dec; 196():208-21. PubMed ID: 25307997
[TBL] [Abstract][Full Text] [Related]
34. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
35. pH-sensitive nano-systems for drug delivery in cancer therapy.
Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
[TBL] [Abstract][Full Text] [Related]
36. Drug delivery to the posterior segment of the eye.
Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
[TBL] [Abstract][Full Text] [Related]
37. Nanotherapy for posterior eye diseases.
Kaur IP; Kakkar S
J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
[TBL] [Abstract][Full Text] [Related]
38. Recent perspectives in ocular drug delivery.
Gaudana R; Jwala J; Boddu SH; Mitra AK
Pharm Res; 2009 May; 26(5):1197-216. PubMed ID: 18758924
[TBL] [Abstract][Full Text] [Related]
39. Nanosize drug delivery system.
Mukherjee B
Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
[TBL] [Abstract][Full Text] [Related]
40. Trends in Nanomedicines for Cancer Treatment.
do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
